Business Wire

CA-ARMIS

22.1.2024 14:01:31 CET | Business Wire | Press release

Share
Cybersecurity Attack Attempts More Than Doubled, Increasing 104% in 2023

Armis, the asset intelligence cybersecurity company, today announced The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape. The 2023 analysis of Armis’ proprietary data offers critical insight into the multifaceted challenges global organizations face when it comes to protecting the entire attack surface. Report findings serve as a blueprint to help security teams worldwide prioritize efforts to reduce cyber risk exposure in 2024.

The report found that global attack attempts more than doubled in 2023, increasing 104%. Utilities (over 200% increase) and Manufacturing (165% increase) were the most at risk industries. Attack attempts peaked in July, with communications devices, imaging devices and manufacturing devices experiencing intensified targeting during this period.

“Armis found that not only are attack attempts increasing, but cybersecurity blind spots and critical vulnerabilities are worsening, painting prime targets for malicious actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “It’s critical that security teams leverage similar intelligence defensively so that they know where to prioritize efforts and fill these gaps to mitigate risk. We hope that by sharing these insights, global businesses and governments will leverage them to immediately pinpoint what they should be focusing on to improve their cybersecurity posture this year to keep critical infrastructure, economies and society safe and secure.”

Key findings of The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape include:

Geopolitical tensions exacerbate the cybersecurity landscape

  • Cyberwarfare grew more widespread in 2023. Top industries exposed to attack from Chinese and Russian actors were those within Manufacturing, Educational Services and Public Administration.
    • In manufacturing, .cn and .ru domains contributed to an average of 30% of monthly attack attempts, while attacks from these domains on Educational Services have risen to about 10% of total attacks.

Legacy technology steepens incline of cybersecurity pros’ existing up-hill battle

  • Older Windows server OS versions (2012 and earlier) are 77% more likely to experience attack attempts compared to newer Windows Server versions.
    • This vulnerability is particularly evident in the server environment, with nearly a quarter of server versions facing end-of-support (EoS) scenarios. The Educational Services industry has a significantly higher percentage of servers (41%) with unpatched weaponized Common Vulnerabilities and Exposures (CVEs), compared to the general average of 10%.
  • Industries still using end-of-life (EoL) or EoS OSs that are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer: Educational Services (18%), Retail (14%), Healthcare (12%), Manufacturing (11%) and Public Administration (10%).

Businesses struggle with effective vulnerability prioritization and remediation

  • There were over 65,000 unique CVEs discovered in 2023.
  • Wearable devices have the highest percentage (93%) of unpatched CVEs.
  • A third of all devices are still not patched for Log4Shell.
  • Patch rates for critical CVEs are not prioritized:
    • Low CVEs: 11% patch rate
    • Medium CVEs: 58% patch rate
    • High CVEs: 64% patch rate
    • Critical CVEs: 55% patch rate
  • Irrespective of the weaponization status of a CVE, organizations consistently grapple with patch rates at 62% for non-weaponized and 61% for weaponized vulnerabilities.

“Blueprints like this report are invaluable as they help teams focus limited resources on efforts with the greatest impact and with the insights to tell data-driven stories in justification of cross-team priorities,” said Curtis Simpson, CISO, Armis. “Using hindsight and analyzed data could allow CISOs to focus 2024 efforts on segmenting legacy technology, prioritizing exposures of greatest significance, and utilizing AI-driven technologies that can assist security teams with defending and managing the attack surface in real-time.”

Proprietary data leveraged for this report was mined from Armis’ Asset Intelligence Engine. The Armis Asset Intelligence Engine is a collective AI-powered knowledge base, monitoring billions of assets worldwide, in order to identify cyber risk patterns and behaviors. It feeds the Armis Centrix™ platform with unique, actionable cyber intelligence to detect and address real-time threats across the entire attack surface.

To read the full report, The Anatomy of Cybersecurity: A Dissection of 2023's Attack Landscape, please visit: https://www.armis.com/anatomy-of-cybersecurity

Learn more about The Armis Asset Intelligence Engine here: https://www.armis.com/platform/armis-asset-intelligence-engine/

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122998889/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye